Lazcluze (Lazertinib) - What is Lazcluze?

Lazcluze (Lazertinib) - Lazertinib is a kinase inhibitor used in combination with amivantamab (Evantumumab) to treat certain patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). Lazcluze, in combination with amivantamab, is indicated for the first-line treatment of adult patients with locally advanced or metastatic (NSCLC) who have an EGFR exon 19 deletion or exon 21 L858R substitution mutation, as tested in a U.S. Food and Drug Administration (FDA)-approved trial.

Non-small cell lung cancer is the most common form of lung cancer, accounting for 80% to 85% of all cases. EGFR mutations occur in 10-15% of Western NSCLC adenocarcinoma patients and 40-50% of Asian patients. EGFR ex19del and EGFR L858R mutations are the most common EGFR mutations. Lazcluze is a third-generation brain-penetrating EGFR tyrosine kinase inhibitor that inhibits EGFR exon 19 deletions and exon 21 L858R substitution mutations at lower concentrations than wild-type EGFR. Amivantamab is an EGFR and methionine-directed bispecific antibody that engages the immune system. The combination serves as a multi-target, chemotherapy-free treatment for non-small cell lung cancer with EGFR ex19del or L858R mutations.

Lazcluze tablets are taken orally once daily with or without food and in combination with amivantamab. Prophylactic anticoagulation is recommended for the first four months of treatment. Common adverse reactions include rash, nail toxicity, infusion-related reactions, musculoskeletal pain, edema, stomatitis, VTE, paresthesias, fatigue, diarrhea, constipation, COVID-19, bleeding, dry skin, decreased appetite, pruritus, nausea, and ocular toxicity.